Fig. 2.
Fig. 2. IFN-γ–dependent inhibition of tumor growth and tumor-induced angiogenesis by α-GalCer. / Wild-type, IFN-γ−/−, or CD1−/− B6 mice were intradermally inoculated with B16-BL6 cells (1 × 105) and then intraperitoneally administered α-GalCer (2 μg/200 μL) or vehicle (200 μL) on days 0, 4, and 8. At 10 days after tumor inoculation, mice were killed and the tumor-inoculated skin was isolated. Tumor size was measured (panel A) and tumor-supplying vessels were counted (panel B). (C) Wild-type, IFN-γ−/−, or CD1−/− B6 mice were intradermally inoculated with B16-BL6 (2 × 106) cells embedded in Matrigel (10 μg/100 μL) and then intraperitoneally administered α-GalCer (2 μg/200 μL) or vehicle (200 μL). At 4 days after inoculation, vessels drawn into the gel were counted. All data are represented as the mean ± SD of 5 mice in each group. Similar results were obtained in 2 independent experiments. *P < .01.

IFN-γ–dependent inhibition of tumor growth and tumor-induced angiogenesis by α-GalCer.

Wild-type, IFN-γ−/−, or CD1−/− B6 mice were intradermally inoculated with B16-BL6 cells (1 × 105) and then intraperitoneally administered α-GalCer (2 μg/200 μL) or vehicle (200 μL) on days 0, 4, and 8. At 10 days after tumor inoculation, mice were killed and the tumor-inoculated skin was isolated. Tumor size was measured (panel A) and tumor-supplying vessels were counted (panel B). (C) Wild-type, IFN-γ−/−, or CD1−/− B6 mice were intradermally inoculated with B16-BL6 (2 × 106) cells embedded in Matrigel (10 μg/100 μL) and then intraperitoneally administered α-GalCer (2 μg/200 μL) or vehicle (200 μL). At 4 days after inoculation, vessels drawn into the gel were counted. All data are represented as the mean ± SD of 5 mice in each group. Similar results were obtained in 2 independent experiments. *P < .01.

Close Modal
This Feature Is Available To Subscribers Only

or Create an Account

Close Modal
Close Modal